KR100815277B1 - Antihyperlipidemia Agent Comprising Red Ginseng Acid Polysaccharide and Lycium Chinense Extract - Google Patents

Abstract

The present invention red ginseng acid polysaccharide (Red ginseng acid polysaccharide: hereinafter referred to as 'RGAP') and goji ( Lycium chinense ) extract, and relates to a nutraceutical composition having enhanced hyperlipidemic function.

In particular, the present invention not only exhibits hyperlipidemia improving function for both cholesterol and triglyceride, but also has hyperlipidemia improving function due to synergistic effects of hyperlipidemia improving function of RGAP and goji berry extract alone.

Hyperlipidemia, triglycerides, cholesterol, red ginseng acid polysaccharide, wolfberry

Description

Antihyperlipidemic agent containing red ginseng acid polysaccharide and goji berry extract {Antihyperlipidemia Agent Comprising Red Ginseng Acid Polysaccharide and Lycium Chinense Extract}

The present invention relates to the continuous invention of the Republic of Korea Patent Application No. 2005-32129 and the Republic of Korea Patent Application No. 2005-32130, more than the red ginseng acid polysaccharide (hereinafter referred to as 'RGAP') having a hyperlipidemic effect It relates to a composition having enhanced effects.

The present invention red ginseng acid polysaccharide (RGAP) and gojija ( Lycium chinense ) extract and exhibits enhanced hyperlipidemic improvement, in particular hyperlipidemia improvement for both cholesterol and triglycerides.

Hyperlipidemia refers to a condition in which fat is high in the blood. This means an increase in plasma cholesterol or triglycerides. Hyperlipidemia is not a symptom by itself, but a problem because it is a risk factor such as atherosclerosis, hypertension, and cardiovascular disease due to the increase of blood cholesterol or triglyceride. Recently, due to the changes in westernized eating habits in Korea, an increasing number of people are obese, hyperlipidemia is accompanied by them. Hyperlipidemia is very important because it can cause atherosclerosis to be life-threatening and cause pancreatitis. In particular, diet is the most basic of all hyperlipidemia symptoms, so daily fat intake should be less than 30%, vegetable fat instead of animal fat, butter, cheese, milk, beef, pork, chicken, chocolate, margarine Many foods that are high in saturated fat, such as low intake should be limited or careful food, many eating disorders. Therefore, it is necessary to develop a functional food material to improve the diet of hyperlipidemic patients or the general public who wants to prevent it.

Cholesterol is essential as a component of cellular plasma membranes, as a source of steroid hormones in the adrenal and gonads, as a source of bile, and as a component of blood lipoproteins. About 80% of cholesterol is synthesized by the liver itself and the remaining 20% is obtained from food. Too much cholesterol biosynthesized in the liver is called endogenous hyperlipidemia, and excessive food intake of high cholesterol content is called exogenous hyperlipidemia. Endogenous hyperlipidemia is often an abnormality in cholesterol metabolism, and exogenous hyperlipidemia occurs when food is ingested excessively. Cholesterol control is the regulation of cholesterol levels within the body to prevent the accumulation of cholesterol in plasma and tissues, especially blood vessels. Hypercholesterolemia occurs when the body's cholesterol accumulates, leading to atherosclerosis if cholesterol is not controlled over a long period of time.

Triglycerides are produced by the absorption of fat from food into the intestine and into the blood or by the excess calories from the liver into the blood, which leads to exogenous hyperlipidemia. High levels of triglycerides in the blood also increase the incidence of cardiovascular disease. In particular, Koreans have a high percentage of carbohydrates in their energy intake, so serum triglyceride levels are important for the determination of hyperlipidemia.

Therefore, among the various natural food ingredients for hyperlipidemia, it is necessary to develop a substance having a function of reducing the concentration of cholesterol or triglycerides that can cause hyperlipidemia while maintaining the cholesterol necessary for the human body.

On the other hand, ginseng, which is known as a medicine for brazier, maturity, ripening, and nerves, has been shown to prevent the development of arteriosclerosis and damage vascular endothelial cells by expanding peripheral blood vessels and improving blood circulation. (ND Kim. Vasorelaxant effect of ginseng and role of endothelium. J. Ginseng Res . 16 (1). 78. 1992). In detail, the results of clinical trials in which Korean ginseng was administered to adult men and women prevented arteriosclerosis, such as the increase of HDL-cholesterol, the improvement of the atherosclerotic index and the decrease of β-lipoprotein. It was found to be effective in (Moshiyama, 1980. 臨 床 と 硏 究, 57 (9), 323, M. Yamamoto, T. Uemura, S. Nkama, M. Uemiya and A. Kumagai. 1983. Serum HDL -cholesterol increasing and fatty liver-improving actions of Panax ginseng in high cholesterol diet-fed rats with clinical effect on hyperlipidemia in man. AJ of Chinese Medicine . 4. 96-101).

In particular, the saponin component of the components of ginseng promotes the enzyme activity associated with the lipid metabolism of cholesterol, and (CN Joo. 1980. The effect of ginseng saponin on hypercholesterolemia induced by prolonged cholesterol feeding in rabbits. Korean Biochemical. J. 13 (1 ), 51-59), have been shown to promote hypercholesterolemia, an important risk factor for atherosclerosis by promoting cholesterol turnover (M. Yamamoto and T. Uemura. 1984. Long-term ginseng effects on hyperlipidaemia in man with further study of its action on atherogenesis and fatty liver in rats. Proc. 4 th Int'l Ginseng Symp . 13-20), Ginsenoside albitus (ginsenoside Rb ₂ ) among ginseng saponins has been shown to improve the arteriosclerosis caused by lowering cholesterol levels, promoting excretion and hypercholesterolemia (T. Yokozawa et. Al. 1985). .. Studies on the mechanism of the hypoglycemic activity of ginsenoside _Rb-2 in streptozotocin-diabetic rats. Chem. Pharm. Bull 33. 869-872) and is known.

Among the components of phosphoric acid, polysaccharides, which are non-saponins, have been reported to have immunomodulatory effect, anticancer effect, antidiabetic effect, and anti-gastric ulcer effect.In China, polysaccharide fractions are used clinically to treat cancer and constant for stomach and colorectal cancer. It is reported to be effective. 21 non-saponin water-soluble substances have been reported from white ginseng, including glycan (panaxan A-U), a glycan. Among them, 8 kinds of acidic polysaccharides are known as neutral polysaccharides. Generally, acidic polysaccharides are polysaccharides in which galacturonic acid, glucuronic acid, and mannuronic acid are combined with polysaccharides, and have a molecular weight of 15,000 or more. In particular, in the case of acidic polysaccharides, cancer cell secretion toxin (Toxohormone L) antagonism, body fat degradation inhibition and cancer patients weight loss inhibitory effect is known. In addition, it has been reported by the present inventors that the acidic polysaccharide fraction of white ginseng has anti-cancer drug (cyclophosphamide) immunotoxicity inhibitory effect, cancer cell (sarcoma-180) transplantation mouse inhibition of cancer development and the phagocytic activity of the net system is enhanced. (Kim, YS et al. 1990. Arch. Pharm. Res., 13: 330). In addition, the Republic of Korea Patent No. 144130 is a protein polysaccharide isolated from white ginseng contains 40 to 50% glucose and galactose, 41 to 45% acidic sugar galacturonic acid, 3.7 to 5.2% protein and molecular weight It is said to exhibit an immunostimulating effect as 50-150 kD. In addition, zinic acid has been reported to show anticancer effects as an immunomodulatory function against mouse lung tumors induced by benzopyrene (BP) and to act as an endogenous cytokine derivative (cytokine inducer), showing an immunologically preventive effect of cancer.

Herbal medicines, which are also used as ingredients for health functional foods, vary in form depending on their origin, place of origin, and numerical methods, and have different constituents and pharmacological activities. Among the herbal medicines used for herbal medicines, there are many examples of using herbal medicines after specific processing, in addition to using fresh ingredients or dried ones. Ginseng is also classified into white and red ginseng according to the value of processing aid. White ginseng is processed by drying ginseng as it is, red ginseng is steamed by drying ginseng (containing about 70% water). As red ginseng steams and dries ginseng, starch is gelatinized and the browning reaction is accelerated, and the appearance is pale brown to reddish brown. The active ingredient in the preparation of red ginseng is accompanied by chemical changes, and saponins, known as ginseng's active ingredients, are partially converted into saponins unique to red ginseng by numerical values during red ginseng production. In addition, such chemical changes also occur in polysaccharides, and the present inventors have discovered that red ginseng acid polysaccharide (RGAP) having a composition different from that of ginseng protein polysaccharide has been registered and patented in Korean Patent No. 450061, and such RGAP is anti-cancer immunity. It is also known that it can be usefully used as a regulator.

Meanwhile, wolfberry ( Lycium Chinense is known to have hypoglycemic and hepatocellular protective effects (ed by Science and Encyclopedia Publishers, 1999. Ingredients and Uses of Herbs, Ilwol Seogwa, Seoul, p.631). Yoon CG, Jeon TW, Oh MJ, Lee GH, Jeong JH. 2000. Effect of the ethanol extract of Lycium chinense on the oxygen free radical and alcohol metabolizing enzyme activities in rats.J. Korean Soc.Food Sci.Nutr 29: 268-273) reported that goji berry extract may lower the possibility of liver damage by inhibiting the production of harmful oxygen by alcohol consumption and increasing the activity of alcohol metabolizing enzymes, Han SH, Shin MK, Lee HS.2001.Effect of Korean Gu-Gi-Ja tea on plasma hormone in Cd-administered rats.J. Korean Soc.Food.Sci.Nutr. 30: 1272-1277) In the experimental group, the cadmium content of the kidney tissue was reported to be significantly lower than that of the cadmium alone. Park YJ, Kim M, Bae SJ. 2002.Enhancement of anti-carcinogenic effect by combination of Lycii fructus with Vitamin CJ Korean Soc.Food Sci.Nutr. 31: 143-148) In addition, Kim NJ, Youn WH, Hong ND. 1994. Pharmacological effects of Lycium chinensis.Kor. J. of Pharmacgnosy. 25: 264-271 It has been reported to have a lowering effect, lowering cholesterol levels, and protecting liver function.

The present inventors confirmed that RGAP, which is completely different from ginseng and saponin or polysaccharide, which is a component of ginseng, specifically reduces the concentration of hyperlipidemia, especially triglycerides, and has filed Korean Patent Application No. 2005-32130. While RGAP has a selective inhibitory effect on triglycerides, RGAP has tried to come up with measures to improve the relatively small effect on cholesterol.

The inventors noted that goji berry extract has a cholesterol lowering effect. However, goji berries have a problem when used alone for the purpose of cholesterol reduction is very small when administered alone.

Surprisingly, the inventors of the present invention have confirmed that the mixed composition of RGAP and goji berry extract suppresses both cholesterol and triglycerides and shows a higher anti-hyperlipidemic synergistic effect than when administered alone.

It is an object of the present invention to provide a health functional food composition capable of lowering both cholesterol and triglyceride levels, particularly enhanced hyperlipidemic function of red ginseng acid polysaccharide (RGAP) having a hyperlipidemic effect.

In order to achieve the above object, the present invention is red ginseng acid polysaccharide (RGAP) and gojija ( Lycium ) for improving hyperlipidemia chinense ) provides a nutraceutical composition containing the extract.

Hyperlipidemia refers to a condition in which the amount of fat in the blood is increased because triglyceride (TG) and cholesterol (Cholesterol) are not properly metabolized. The causes of hyperlipidemia are largely divided into external factors such as food, and internal factors such as genetic and lipid metabolism abnormalities. About 80% of cholesterol is synthesized by the liver itself and the remaining 20% is obtained from food. Endogenous hyperlipidemia is often an abnormality in cholesterol metabolism, and exogenous hyperlipidemia is caused by excessive intake of high cholesterol food from food. Triglycerides are produced by the absorption of fat from food into the blood in the intestine and into the blood after excess calories from the liver are converted into fat, so eating a lot of fatty foods is likely to cause endogenous hyperlipidemia.

Therefore, in order to improve hyperlipidemia caused by westernized diet and internal factors, it is necessary to control lipid metabolism abnormalities, and it has been required to develop functional food materials capable of smoothing metabolic abnormalities of cholesterol and triglycerides.

As described in Korean Patent Application No. 2005-32129 and Korean Patent Application No. 2005-32130, red ginseng acid polysaccharide (RGAP) is specific for triglyceride content while maintaining a constant cholesterol level in exogenous hyperlipidemia. As a result, the concentration is decreased, and in endogenous hyperlipidemia, cholesterol and triglyceride levels are decreased together.

The present invention relates to a composition having an improved hyperlipidemic effect, wherein the herbal composition containing the RGAP and goji berry extract of the present invention simultaneously reduces the concentration of triglycerides and cholesterol in both exogenous hyperlipidemia and endogenous hyperlipidemia. It can be effectively used for improvement.

Hereinafter, the present invention will be described in detail.

RGAP of the present invention is isolated from red ginseng, glucuronic acid (glucuronic acid) 41.6 to 60.0 mol%, galacturonic acid (galacturonic acid) 2.5 to 7.5 mol%, glucose (glucose) 18.8 to 33.4 mol%, arabinose ( arabinose) is an acidic polysaccharide comprising 1.1 to 2.1 mol%, molecular weight of 12,000 to 450,000. The RGAP is preferably prepared by the method of Korean Patent No. 4,50061.

In addition, the wolfberry extract of the present invention is prepared according to the conventional herbal medicine extraction method, 8 times water (v / w) is added to the wolfberry fruit, extracted three times at 85 ℃ 4 times, filtered (whatman 41 times) and concentrated After lyophilization.

The present invention can be ingested by mixing or in combination with RGAP and goji extract to simultaneously reduce the triglyceride and cholesterol concentrations of exogenous hyperlipidemia or endogenous hyperlipidemia by diet. The herbal extract of RGAP and goji berry extract may be ingested in a 1: 2 to 1: 3 weight ratio, preferably in a 1: 2 weight ratio, but is not limited thereto.

And the present invention can be prepared by a known method by adding the herbal composition to a conventional palatable food, can be prepared in a variety of foods, and also can be formulated in a general formulation, other ingredients other than the above components are those skilled in the art according to the formulation Can be selected and blended suitably.

Hereinafter, the present invention will be described in detail by examples. However, the following examples are only for illustrating the present invention, and the scope of the present invention is not limited by the examples.

Preparation Example 1 Preparation of Red Ginseng Acid Polysaccharide (RGAP)

RGAP was prepared as follows according to the method described in Korean Patent No. 4,50061.

10 g of red ginseng was added to 10 kg of 85% ethanol, and extracted three times at 70 ° C., followed by centrifugation to recover the residue. The aqueous extract was dialyzed with distilled water for 4 days in a refrigerating chamber using a dialysis membrane having a molecular weight cut-off value of 12 kD or more to obtain a polymer dialysis solution of 12 kD or more, which was centrifuged at 8,000 rpm for 20 minutes to obtain a supernatant. RGAP was prepared by freezing and drying the precipitate obtained by adding 85% ethanol 5 times the weight of the supernatant to the supernatant and centrifuging (8,000 rpm, 30 minutes) therefrom.

Preparation Example 2 Preparation of Wolfberry Extract

8 L of water was added to 1 kg of goji berry, extracted three times at 85 ° C. for 4 hours, filtered and concentrated, and the concentrate was lyophilized to prepare a goji berry extract.

Preparation Examples 3 to 5 Preparation of Red Ginseng Acid Polysaccharide and Goji Extract

RGAP 100 mg / kg of Preparation Example 1 and wolfberry of Preparation Example 2 ( Lycium chinense ; LC) 100, 200 and 300 mg / kg extracts were mixed in a weight ratio of 1: 1, 1: 2 and 1: 3, respectively, to prepare the compositions of Preparation Examples 3 to 5.

Example 1 Preparation of Tablet

To 5.0% by weight of the herbal composition prepared in Preparation Example 4, 65.0% by weight of starch, 17.5% by weight of lactose, 5.0% by weight of magnesium stearate, 2.5% by weight of vitamin C, 5.0% by weight of mannitol, and the herbal medicine by a conventional tablet manufacturing method Tablets containing the composition were prepared.

Example 2 Preparation of Capsule

To 5.0% by weight of the herbal composition prepared in Preparation Example 3, 90.0% by weight of carboxymethyl cellulose and 5.0% by weight of magnesium stearate were blended and filled into capsules by a conventional method for preparing a capsule, thereby preparing a capsule containing the herbal composition.

Example 3 Preparation of Noodles

7% by weight of the herbal composition powder prepared in Preparation Example 5, 48% by weight of wheat flour, 37% by weight starch, 8% by weight of black soybean powder was prepared, and noodles containing the herbal composition was prepared by a conventional noodle manufacturing method.

Example 4 Preparation of Beverage

To 7.0% by weight of the herbal composition prepared in Preparation Example 4, concentrated apple juice 13.0% by weight, vitamin C 2.0% by weight, citric acid 15.0% by weight, trisodium citrate 2.5% by weight, drink flavora, sodium benzoate 2.5% by weight and the rest Was prepared by mixing purified water with sterilization for 20 seconds at 90 ℃ or more and then sterilizing for 30 minutes at 85 ℃ to prepare a beverage containing a herbal composition.

< Experimental Example  1> Antihyperlipidemic Effect Experiment

end. Experiment method

100 mg / kg and 300 mg / kg of RGAP prepared in Preparation Example 1, 200mg / kg and 300mg / kg of Gojija extract of Preparation Example 2, prepared in Preparation Example 4 in rats (SP.D rat, about 200g) Each of the prepared herbal compositions (1: 2 weight ratio) 300 mg / kg was orally administered once / day for 3 days and then fasted for 12 hours. One hour after oral administration of each sample, Triton WR-1339 was administered to the tail vein of the rat (200 mg / kg) to induce hyperlipidemia. After 2 hours, blood was collected, and the index of hyperlipidemia was measured by a biochemical analyzer (Automatic Analyzer, Hitachi 7020, Tokyo, Japan), and the results are shown in Table 1. The normal group was a group that did not cause hyperlipidemia, and the control group was a group treated with Triton and not treated in the same manner as the sample group.

Inhibition rate compared to the control group in the sample administration group was expressed by the calculation method of ((blood concentration of the control group-blood concentration of the sample administration group) / (blood concentration of the control group-blood concentration of the normal group) x 100.

I. Experiment result

Test group Dose (mg / kg) Total Cholesterol (total chlolesterol) (mg / dl) Triglyceride (mg / dl) Triton sample   Normal - -   63.9 ± 10.9   70.3 ± 20.0   Control 200 - 127.4 ± 18.2 ^** 474.3 ± 52.7 ^** RGAP 100 200 100  125.0 ± 25.7 (3.8%)  437.3 ± 90.9 (9.2%) LC 200 200 200  121.5 ± 17.9 (9.3%)  463.9 ± 80.9 (2.6%) RGAP 300 200 300  124.9 ± 19.8 (3.9%)  412.6 ± 87.6 (15.3%) LC 300 200 300  120.1 ± 16.5 (11.5%)  421.2 ± 95.4 (13.1%) Herbal Composition (1: 2) (RGAP100mg / kg + LC 200mg / kg) 200 300 94.8 ± 9.0 ^{**, ##} (51.3%) 341.4 ± 98.8 ^{**, #} (32.9%) RGAP: red ginseng acid polysaccharide, LC: goji berry extract *, ** p <0.05, p <0.01 normal control vs control #, ## p <0.05, p <0.01 control vs administration ():% inhibition compared to control

As can be seen in Table 1, in the hyperlipidemia-induced triglyceride-induced rats, the total cholesterol content was 63.9 mg / dL in the normal group and 127.4 mg / dL in the control group, causing about two-fold increase in concentration. The fat content of 70.3 mg / dl of the normal group was 474.3 mg / dl of the control group, which was induced by an increase of about 7 times, indicating that each concentration was inhibited by each sample.

In the case of 100 and 300 mg / kg administration alone, the total cholesterol content in blood was inhibited by 3.8% and 3.9%, and the administration of goji berry extract 200 and 300 mg / kg alone was only 9.3% and 11.5% inhibition. In the case of the composition (RGAP 100 mg / kg + LC 200 mg / kg) by inhibiting the blood total cholesterol content by 51.3%, it can be seen that the herbal composition of the present invention significantly increased the blood total cholesterol inhibition rate than the single administration group. From the above results, it can be seen that the total cholesterol reduction effect of the present invention is very excellent due to the synergistic effect.

In addition, RGAP alone inhibited 9.2% and 15.3% in the content of triglyceride in the blood by 100 and 300 mg / kg, whereas 200 and 300 mg / kg administration of Goji extract alone inhibited only 2.6% and 13.1%. In the case of the composition (RGAP 100mg / kg + LC 200mg / kg) by inhibiting the blood triglyceride content by 32.9%, it can be seen that the herbal composition of the present invention significantly increased the blood triglyceride inhibition rate than the single administration group. The experimental results indicate that the effect of reducing triglycerides in the blood of the present invention shows a synergistic effect and is very excellent.

Therefore, the present invention not only showed an improvement in hyperlipidemia for both cholesterol and triglycerides, but also showed a very synergistic effect of reducing cholesterol and triglycerides compared to RGAP and goji extract.

< Experimental Example  2> Comparison of antihyperlipidemic effect according to the change of composition ratio of the present invention

end. Experiment method

RGAP 100 mg / kg of Preparation Example 1 and wolfberry of Preparation Example 2 ( Lycium chinense ; LC) Extract 100, 200, 300 mg / kg of each of the preparations 3 to 5 in a ratio of 1: 1, 1: 2, 1: 3 each composition according to the method of Experimental Example 1 once / day After 3 days of oral administration and fasting for 12 hours. After oral administration of the herbal composition once again, Triton (WR-1339) was administered to the tail vein of rats (200 mg / kg) to induce hyperlipidemia. After 2 hours, blood was collected, and the index of hyperlipidemia was measured by a biochemical analyzer (Automatic Analyzer, Hitachi 7020, Tokyo, Japan), and the results are shown in Table 2. The normal group was a group that did not cause hyperlipidemia, and the control group was a group treated with Triton and not treated in the same manner as the sample group.

The inhibition rate was expressed by the calculation method of "(blood concentration of control group-blood concentration of sample administration group) / (blood concentration of control group-blood concentration of normal group) x 100".

I. Experiment result

Test group (n = 10) Single dose (mg / kg)   Total cholesterol (mg / dl) Triglycerides (mg / dl) Triton sample  Normal - - 63.9 ± 11.0 70.3 ± 20.0  Control 200 - 127.4 ± 18.2 ^** 474.3 ± 52.7 ^** Preparation Example 3 200 200 119.5 ± 30.6 ^** (12.4%) 425.0 ± 118.3 ^** (12.2%) Preparation Example 4 200 300 94.8 ± 9.0 ^{**, ##} (51.3%) 341.4 ± 98.8 ^{**, ##} (32.9%) Preparation Example 5 200 400 110.1 ± 18.3 ^** (27.2%) 342.8 ± 48.5 ^{**, ##} (32.5%)  *, **: p <0.05, p <0.01 normal vs control #, ##: p <0.05, p <0.01 control vs sample administration RGAP: red ginseng polysaccharide, LC: goji berry extract (): blood concentration inhibition%

As shown in Table 2, the herbal composition (1: 1 weight ratio) administration group of Preparation Example 3 had a total cholesterol content of 119.5 mg / dl and a triglyceride content of 425.0 mg / dl, inhibiting 12.4% and 12.2%, respectively. The herbal composition (1: 2 weight ratio) administration group of Preparation Example 4 had a total cholesterol content of 94.8 mg / dl and a triglyceride content of 341.4 mg / dl, inhibiting 51.3% and 32.9%, respectively. (1: 3 weight ratio) The administration group showed a total cholesterol content of 110.1 mg / dl and a triglyceride content of 342.80 mg / dl, inhibiting 27.2% and 32.5%, respectively.

Therefore, the herbal compositions of Preparation Examples 3 to 5 had higher or equivalent inhibitory effect of cholesterol and triglyceride than the alone administration group according to Table 1 of Experimental Example 1, and the herbal extracts of RGAP and goji berry extract showed synergistic effect even if not in a specific ratio. It can be seen.

The present invention red ginseng acid polysaccharide (RGAP) and gojija ( Lycium chinense ) extract, and provides a nutraceutical composition with enhanced hyperlipidemia improving function.

In particular, the present invention not only exhibits hyperlipidemia improving function for both cholesterol and triglyceride, but also has hyperlipidemia improving function due to synergistic effects of hyperlipidemia improving function of RGAP and goji berry extract alone.

Therefore, the present invention can be usefully used as a diet for the improvement of hyperlipidemia caused by the dietary and genetic factors of modern people with high fat intake by reducing both the concentration of cholesterol as well as triglycerides.

Claims (2)

Glucuronic acid 41.6 to 60.0 mol%, galacturonic acid 2.5 to 7.5 mol%, glucose 18.8 to 33.4 mol% and arabinose 1.1 to 2.1 mol% Red ginseng acid polysaccharide (RGAP) and Lycium chinense extract having a molecular weight of 12,000 to 450,000 as an active ingredient, the weight ratio of the red ginseng acid polysaccharide and Goji extract is a weight ratio of 1: 2. Pharmaceutical composition for preventing and treating endogenous hyperlipidemia. 2. The pharmaceutical composition for preventing and treating hyperlipidemia according to claim 1, wherein the prevention and treatment of endogenous hyperlipidemia decreases the concentration of cholesterol and triglyceride.